SecBot SecBot
PRESS-RELEASE ·Filed Feb 27, 2026

CGON

CG Oncology Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor upcoming topline data from PIVOT-006 and CORE-008 Cohort CX in 1H 2026, which could serve as key value inflection points. The expanded cash runway into 2029 reduces near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$58.80
T+0 close · Feb 27, 2026 · via day close
Latest settled
+5.26%
T+60 · $61.89
Vs SPY
−4.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 27 $58.80entry
  2. T+1 · 9mo ago −1.77%α −1.82% · $57.76
  3. T+5 · 9mo ago +5.24%α +7.22% · $61.88
  4. T+20 · 8mo ago +9.90%α +17.45% · $64.62
  5. T+60 · 6mo ago +5.26%α −4.13% · $61.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology reported financial results for Q4 and full year 2025, highlighting a cash position of $742.2 million as of December 31, 2025, with an increase to $903.0 million by February 26, 2026, due to ATM share sales. The company expects this cash to fund operations into the first half of 2029. Key upcoming catalysts include topline Phase 3 data from the PIVOT-006 trial in intermediate-risk NMIBC and Phase 2 combination data from CORE-008 Cohort CX, both expected in the first half of 2026.

Key Financial Metrics

Revenue
$4.0M
+254.7% YoY
EPS
$-2.08

Key Facts

  • Cash, cash equivalents, and marketable securities were $742.2 million as of December 31, 2025, and increased to $903.0 million by February 26, 2026.
  • Net loss attributable to common stockholders was $161.0 million for full year 2025, up from $88.0 million in 2024.
  • R&D expenses increased to $116.6 million in 2025 from $82.1 million in 2024; G&A rose to $73.5 million from $33.7 million.
  • Topline Phase 3 data from PIVOT-006 trial in intermediate-risk NMIBC expected in 1H 2026.
  • First results from Phase 2 CORE-008 Cohort CX (cretostimogene + gemcitabine) in high-risk NMIBC expected in 1H 2026.
  • BLA submission for HR BCG-unresponsive NMIBC planned for 2026.

Financial Impact

Cash increased by ~$160.8 million in Q4 2025 and early 2026 via ATM equity sales; net loss widened to $161.0 million in 2025 from $88.0 million in 2024.

cashnet lossr&dg&a

Risk Factors

  • Clinical trial results may not meet expectations, particularly in registrational trials like PIVOT-006.
  • Increased operating expenses and widening net losses could pressure valuation if revenue milestones are delayed.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3246513

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 28, 2026